^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Mantle Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY...Preferred regimens...Ibrutinib+/-rituximab Mantle Cell Lymphoma….MAINTENANCE AFTER HDT/ASCR OR AGGRESSIVE INDUCTION THERAPY….Covalent BTKi x 2 years (category 2A for ibrutinib; category 2B for acalabrutinib or zanubrutinib) + rituximab every 8 weeks x 3 y (category 1 for rituximab following HDT/ASCR)